Search
Now showing items 1-1 of 1
Optimizing doses of ceftolozane/tazobactam as monotherapy or in combination with amikacin to treat carbapenem-resistant pseudomonas aeruginosa
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a hospital-acquired pathogen with a high mortality rate and limited treatment options. We investigated the activity of ceftolozane/tazobactam (C/T) and its synergistic ...